Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 15, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,406 pence per share.
Material Changes
On March 15, 2007, the Company purchased 500,000 Ordinary shares of 25 pence each. Following this transaction, the total number of shares held in Treasury increased to 263,672,678. The total number of shares in issue (excluding Treasury shares) stands at 5,745,903,000.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Share Repurchase: 500,000 shares purchased on March 15, 2007, at 1,406 pence per share.
- Treasury Holdings: Total Treasury shares now stand at 263,672,678.
- Shares in Issue: 5,745,903,000 shares (excluding Treasury shares) represent total voting rights.
- Regulatory Compliance: The transaction was executed under authority granted by shareholders on May 17, 2006.